Payment overview · 2025
General Payments
$454.85
22 reported records · 14 companies
Healthcare provider profile · identity verified
Nishant U Patel, MD
Allopathic & Osteopathic Physicians|Family Medicine · MODESTO, CA · NPI 1902399231
Verified facts
What the public records show
CMS Open Payments records show Nishant U Patel, MD received $454.85 in general payments during 2025 across 22 reported records.
GlaxoSmithKline, LLC. accounted for 17.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $80.81 | 17.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $56.02 | 12.3% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $53.09 | 11.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.71 | 10.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.60 | 9.4% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.73 | 6.5% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $26.37 | 5.8% | 1 | 2025 |
| Exeltis, USA Inc. | Unresolved — no canonical attribution shown | $20.16 | 4.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.58 | 4.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.03 | 4.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.03 | 4.0% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $16.64 | 3.7% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $15.60 | 3.4% | 1 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $13.48 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $454.85 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $53.09 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $40.91 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $39.90 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $39.90 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $38.26 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $38.26 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $38.26 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $27.75 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.75 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| SLYND Normalized: slynd |
Drug | Exeltis, USA Inc. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $15.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 126 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
126 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
48 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 463 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 298 | 89 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 267 | 45 |
| Lisinopril | Lisinopril | 243 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 216 | 66 |
| Alprazolam | Alprazolam | 187 | 33 |
| Omeprazole | Omeprazole | 179 | 58 |
| Mounjaro | Tirzepatide | 176 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 47 |
| Metformin Hcl | Metformin Hcl | 166 | 51 |
| Losartan Potassium | Losartan Potassium | 163 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 158 | 53 |
| Gabapentin | Gabapentin | 146 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 42 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 138 | 20 |
| Tramadol Hcl | Tramadol Hcl | 137 | 33 |
| Trazodone Hcl | Trazodone Hcl | 132 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 131 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 41 |
| Ozempic | Semaglutide | 126 | 29 |
| Celecoxib | Celecoxib | 123 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 33 |
| Baclofen | Baclofen | 107 | 26 |
| Furosemide | Furosemide | 107 | 44 |
| Lorazepam | Lorazepam | 107 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 16 |
| Simvastatin | Simvastatin | 101 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 36 |
| Sertraline Hcl | Sertraline Hcl | 89 | 24 |
| Pregabalin | Pregabalin | 88 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 85 | 27 |
| Metformin Hcl Er | Metformin Hcl | 84 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 19 |
| Carvedilol | Carvedilol | 78 | 24 |
| Ondansetron Odt | Ondansetron | 77 | 34 |
| Clonazepam | Clonazepam | 74 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 72 | 21 |
| Montelukast Sodium | Montelukast Sodium | 70 | 19 |
| Jardiance | Empagliflozin | 69 | 20 |
| Morphine Sulfate Er | Morphine Sulfate | 67 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 22 |
| Donepezil Hcl | Donepezil Hcl | 65 | 19 |
| Alendronate Sodium | Alendronate Sodium | 64 | 20 |
| Testosterone Cypionate | Testosterone Cypionate | 64 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 62 | 11 |
| Ibuprofen | Ibuprofen | 61 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 18 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 57 | 23 |
| Meloxicam | Meloxicam | 53 | 16 |
| Famotidine | Famotidine | 52 | 16 |
| Atenolol | Atenolol | 51 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 20 |
| Lidocaine | Lidocaine | 51 | 26 |
| Bumetanide | Bumetanide | 50 | 11 |
| Cefdinir | Cefdinir | 49 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 18 |
| Eliquis | Apixaban | 48 | 15 |
| Memantine Hcl | Memantine Hcl | 48 | suppressed |
| Lansoprazole | Lansoprazole | 47 | 19 |
| Metoclopramide Hcl | Metoclopramide Hcl | 47 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 14 |
| Potassium Chloride | Potassium Chloride | 46 | 12 |
| Temazepam | Temazepam | 46 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 44 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 42 | 13 |
| Estradiol | Estradiol | 42 | 13 |
| Lovastatin | Lovastatin | 40 | suppressed |
| Prednisone | Prednisone | 39 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | 11 |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 16 |
| Allopurinol | Allopurinol | 36 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 36 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 36 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 14 |
| Fluconazole | Fluconazole | 35 | 18 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 35 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 27 |
| Diazepam | Diazepam | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Rybelsus | Semaglutide | 34 | suppressed |
| Finasteride | Finasteride | 33 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | 13 |
| Azithromycin | Azithromycin | 32 | 27 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 31 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Sucralfate | Sucralfate | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 22 |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | 15 |
| Glipizide Er | Glipizide | 23 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Fentanyl | Fentanyl | 22 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 19 |
| Glipizide | Glipizide | 20 | suppressed |
| Movantik | Naloxegol Oxalate | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Oxycontin | Oxycodone Hcl | 16 | suppressed |
| Praluent Pen | Alirocumab | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Embrace Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | 11 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 11 | suppressed |
| Metaxalone | Metaxalone | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Relistor | Methylnaltrexone Bromide | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $454.85 · 22 records | GlaxoSmithKline, LLC. | ABRYSVO, APRETUDE, AREXVY, CAPVAXIVE, COMIRNATY, DUPIXENT, EVENITY, EVKEEZA, FREESTYLE LIBRE 3, GARDASIL 9, LEQVIO, M-M-R II, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, REPATHA, Rybelsus, SHINGRIX, SLYND, TRELEGY ELLIPTA, Wegovy, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error